The effect of anti-interleukin 2 monoclonal antibody treatment on the survival of rat cardiac allograft

Kenichi Sakagami, Toshihide Ohsaki, Tetsuya Ohnishi, Shinya Saito, Junji Matsuoka, Kunzo Orita

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The effect of anti-interleukin 2 monoclonal antibody (anti-IL2 MoAb) and the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb were examined in heterotopic rat cardiac allografts. Mouse anti-human recombinant IL2 MoAb was obtained by the hybridoma technique. The anti-IL2 MoAb, termed 8H-10, was an IgG2a which inhibited IL2-driven [3H]TdR incorporation in cytolytic T lymphocyte line cells at a dilution of 26. 8H-10 was injected iv at a dose of 200 μg/day for 8 consecutive days, beginning on the day of transplantation. Hearts from F344 rats (RT11v1) were transplanted into ACI recipient rats (RT11v1). The mean survival time was 7.6 ± 0.8 days in untreated controls, 9.0 ± 1.2 days in additional controls treated with mouse anti-sheep red blood cell monoclonal antibody, and 25.3 ± 18.4 days in the anti-IL2 MoAb (8H-10)-treated group (P <0.05). Furthermore, the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb (8H-10) was specifically seen in the grafted heart. In conclusion, these results suggest that IL2 may play an important role in allograft rejection and that anti-IL2 MoAb may serve as a useful immunosuppressive agent in clinical transplantation.

Original languageEnglish
Pages (from-to)262-266
Number of pages5
JournalJournal of Surgical Research
Volume46
Issue number3
DOIs
Publication statusPublished - 1989

Fingerprint

Interleukin-2
Allografts
Monoclonal Antibodies
Inbred ACI Rats
Transplantation
Inbred F344 Rats
Hybridomas
Immunosuppressive Agents
Sheep
Erythrocytes
T-Lymphocytes

ASJC Scopus subject areas

  • Surgery

Cite this

The effect of anti-interleukin 2 monoclonal antibody treatment on the survival of rat cardiac allograft. / Sakagami, Kenichi; Ohsaki, Toshihide; Ohnishi, Tetsuya; Saito, Shinya; Matsuoka, Junji; Orita, Kunzo.

In: Journal of Surgical Research, Vol. 46, No. 3, 1989, p. 262-266.

Research output: Contribution to journalArticle

Sakagami, Kenichi ; Ohsaki, Toshihide ; Ohnishi, Tetsuya ; Saito, Shinya ; Matsuoka, Junji ; Orita, Kunzo. / The effect of anti-interleukin 2 monoclonal antibody treatment on the survival of rat cardiac allograft. In: Journal of Surgical Research. 1989 ; Vol. 46, No. 3. pp. 262-266.
@article{665cccc8ec6a474b9c30b80bb17e2fe7,
title = "The effect of anti-interleukin 2 monoclonal antibody treatment on the survival of rat cardiac allograft",
abstract = "The effect of anti-interleukin 2 monoclonal antibody (anti-IL2 MoAb) and the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb were examined in heterotopic rat cardiac allografts. Mouse anti-human recombinant IL2 MoAb was obtained by the hybridoma technique. The anti-IL2 MoAb, termed 8H-10, was an IgG2a which inhibited IL2-driven [3H]TdR incorporation in cytolytic T lymphocyte line cells at a dilution of 26. 8H-10 was injected iv at a dose of 200 μg/day for 8 consecutive days, beginning on the day of transplantation. Hearts from F344 rats (RT11v1) were transplanted into ACI recipient rats (RT11v1). The mean survival time was 7.6 ± 0.8 days in untreated controls, 9.0 ± 1.2 days in additional controls treated with mouse anti-sheep red blood cell monoclonal antibody, and 25.3 ± 18.4 days in the anti-IL2 MoAb (8H-10)-treated group (P <0.05). Furthermore, the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb (8H-10) was specifically seen in the grafted heart. In conclusion, these results suggest that IL2 may play an important role in allograft rejection and that anti-IL2 MoAb may serve as a useful immunosuppressive agent in clinical transplantation.",
author = "Kenichi Sakagami and Toshihide Ohsaki and Tetsuya Ohnishi and Shinya Saito and Junji Matsuoka and Kunzo Orita",
year = "1989",
doi = "10.1016/0022-4804(89)90068-1",
language = "English",
volume = "46",
pages = "262--266",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - The effect of anti-interleukin 2 monoclonal antibody treatment on the survival of rat cardiac allograft

AU - Sakagami, Kenichi

AU - Ohsaki, Toshihide

AU - Ohnishi, Tetsuya

AU - Saito, Shinya

AU - Matsuoka, Junji

AU - Orita, Kunzo

PY - 1989

Y1 - 1989

N2 - The effect of anti-interleukin 2 monoclonal antibody (anti-IL2 MoAb) and the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb were examined in heterotopic rat cardiac allografts. Mouse anti-human recombinant IL2 MoAb was obtained by the hybridoma technique. The anti-IL2 MoAb, termed 8H-10, was an IgG2a which inhibited IL2-driven [3H]TdR incorporation in cytolytic T lymphocyte line cells at a dilution of 26. 8H-10 was injected iv at a dose of 200 μg/day for 8 consecutive days, beginning on the day of transplantation. Hearts from F344 rats (RT11v1) were transplanted into ACI recipient rats (RT11v1). The mean survival time was 7.6 ± 0.8 days in untreated controls, 9.0 ± 1.2 days in additional controls treated with mouse anti-sheep red blood cell monoclonal antibody, and 25.3 ± 18.4 days in the anti-IL2 MoAb (8H-10)-treated group (P <0.05). Furthermore, the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb (8H-10) was specifically seen in the grafted heart. In conclusion, these results suggest that IL2 may play an important role in allograft rejection and that anti-IL2 MoAb may serve as a useful immunosuppressive agent in clinical transplantation.

AB - The effect of anti-interleukin 2 monoclonal antibody (anti-IL2 MoAb) and the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb were examined in heterotopic rat cardiac allografts. Mouse anti-human recombinant IL2 MoAb was obtained by the hybridoma technique. The anti-IL2 MoAb, termed 8H-10, was an IgG2a which inhibited IL2-driven [3H]TdR incorporation in cytolytic T lymphocyte line cells at a dilution of 26. 8H-10 was injected iv at a dose of 200 μg/day for 8 consecutive days, beginning on the day of transplantation. Hearts from F344 rats (RT11v1) were transplanted into ACI recipient rats (RT11v1). The mean survival time was 7.6 ± 0.8 days in untreated controls, 9.0 ± 1.2 days in additional controls treated with mouse anti-sheep red blood cell monoclonal antibody, and 25.3 ± 18.4 days in the anti-IL2 MoAb (8H-10)-treated group (P <0.05). Furthermore, the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb (8H-10) was specifically seen in the grafted heart. In conclusion, these results suggest that IL2 may play an important role in allograft rejection and that anti-IL2 MoAb may serve as a useful immunosuppressive agent in clinical transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0024519190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024519190&partnerID=8YFLogxK

U2 - 10.1016/0022-4804(89)90068-1

DO - 10.1016/0022-4804(89)90068-1

M3 - Article

C2 - 2646474

AN - SCOPUS:0024519190

VL - 46

SP - 262

EP - 266

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 3

ER -